Results 101 to 110 of about 3,287,144 (299)

Assessment Rate of Being Conscious and Quality of Informed Consent Process in Inpatients Undergoing Surgery in Selected Hospitals of Isfahan in 2009

open access: yesMajallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Qum, 2011
Background and Objectives: Informed consent of patient is the basis of medical ethics. Complying with standards of informed consent process in curative activities directly influence patient satisfaction during the treatment process, thus reducing ...
N Mirbagher Ajorpaz   +3 more
doaj  

INFORMED CONSENT IN MEDICAL RESEARCH

open access: yes, 2001
Contributors -- Foreword / Richard Smith -- Introduction / Len Doyal and Jeffrey S. Tobias -- Pt. I. Informed consent and medical research: a historical perspective -- Ch. 1. The Nuremberg code and the Helsinki declaration -- Ch. 2.

core  

Informed Consent and Moral Integrity

open access: yes, 1989
Informed consent is required for any medical procedure although the situations in which it is given are beset by uncertainties and indeterminacies. These make medico-legal scrutiny of such situations very difficult.
Gillett, Grant R.
core   +1 more source

DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients

open access: yesMolecular Oncology, EarlyView.
Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen   +14 more
wiley   +1 more source

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

open access: yesMolecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy   +10 more
wiley   +1 more source

INFORMED CONSENT – RIGHT OR BURDEN

open access: yesZdravniški Vestnik, 2016
Informed consent is legal institute that was introduced in the research area to prevent possible abuses in human research. Almost a century later it was introduced also in general medicine outside the research area.
Borut Stražišar, Branka Stražišar
doaj  

Clinical performance of the urine‐based TERT promoter AbsoluteQ Digital PCR for non‐invasive detection of bladder cancer

open access: yesMolecular Oncology, EarlyView.
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel   +12 more
wiley   +1 more source

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

open access: yesMolecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens   +6 more
wiley   +1 more source

Is Informed Consent Effective in Trauma Patients?

open access: yes, 2008
BACKGROUND: Informed consent in the modern era is a common and important topic both for the well-informed patient and to prevent unnecessary litigation. However, the effectiveness of informed consent in trauma patients is an under-researched area.
Bhangu, A.   +3 more
core   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

open access: yesMolecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy